Management ChangeJun 2, 2026, 04:08 PM
Chemomab Therapeutics Appoints Gwen Melincoff to Board, Announces Committee Changes
AI Summary
Chemomab Therapeutics Ltd. announced several changes to its Board of Directors and committee assignments. Gwen Melincoff was appointed as a Class I Director and will chair the Nominating and Governance Committee. Concurrently, Claude Nicaise and Jill Quigley resigned from their positions as directors and members of the Audit Committee. Neil Cohen and Dr. Nissim Darvish were appointed to the Audit Committee, with Mr. Cohen also resigning from his role as Chair of the Nominating Committee. Following these changes, the Board will comprise five directors.
Key Highlights
- Gwen Melincoff appointed as Class I Director to Chemomab Therapeutics' Board.
- Ms. Melincoff also appointed Chair of the Nominating and Governance Committee.
- Claude Nicaise resigned as a director and Audit Committee member.
- Jill Quigley resigned as a director and Audit Committee member.
- Neil Cohen and Dr. Nissim Darvish appointed to the Audit Committee.
- Neil Cohen resigned as Chair of the Nominating Committee.
- The Board of Directors now consists of five directors.
Price Impact
More from CMMB